We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...
US-based LifeMine Therapeutics has dosed the first subject in the Phase I trial of calcineurin inhibitor (CNi), LIFE-001, intended as a “prelude” to immune-mediated disorders and organ transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback